Süleyman KARAKÖSE, Ayşe Zeynep BAL, Eylem Pınar ESER, Murat DURANAY

The effect of rituximab on encapsulated peritoneal sclerosis in an experimental rat model

Background/aim: Peritoneal sclerosis may be observed in varied manifestations. However, the most serious form is the encapsulatedperitoneal sclerosis. We researched the effect of rituximab on peritoneal fibrosis in an experimental rat model.Materials and methods: Twenty-four Wistar Albino rats were divided into 4 equal groups. During weeks 0–3; group I received isotonicsaline (IS) solution, group II, group III, and group IV received chlorhexidine gluconate (CG) via intraperitoneal (i.p.) route. In the next3 weeks nothing adminestred to both group I and group II but IS solution was adminestred to group III via i.p. route and 375 mg/m2/week rituximab was applied intravenously on days 21, 28, and 35 to group IV. Fibrosis, peritoneal thickness, and inflammation wereevaluated. Immunohistochemical methods used for the detection of matrix MMP-2, TGF-β1, and VGEF expressions.Results: The rituximab (group IV) had significantly lower fibrosis and peritoneal thickness scores than the group II and III (P < 0.001).TGF-β1 and VEGF expressions were significantly lower in the rituximab group than in the group II and III (P < 0.001).Conclusion: We found that rituximab had a significant effect on the peritoneal thickness, total fibrosis, TGF-β1 and VGEF scores whichwere induced by CG.

PDF

___

1. Caicedo L, Delgado A, Caicedo LA, Bravo JC, Thomas LS et al. Sclerosing encapsulated peritonitis: a devastating and infrequent disease complicating kidney transplantation, case report and literature review. International Journal of Surgery Case Reports 2017; 33: 135-138.
2. Latus J, Ulmer C, Fritz P, Rettenmaier B, Biegger D et al. Phenotypes of encapsulating peritoneal sclerosis— macroscopic appearance, histologic findings, and outcome. Peritoneal Dialysis International 2013; 33 (5): 495-502.
3. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nature Reviews Immunology 2011; 11(11): 723-737.
4. Bosello S, De Luca G, Tolusso B, Lama G, Angelucci C et al. B cells in systemic sclerosis: A possible target for therapy. Autoimmunity Reviews 2011; 10(10): 624-630.
5. Ro Y, Hamada C, Inaba M, Io H, Kaneko K et al. Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrology Dialysis Transplantation 2007; 22(10): 2838-2848.
6. Hirahara I, Inoue M, Okuda K, Ando Y, Muto S et al. The potential of matrix metalloproteinase–2 as a marker of peritoneal injury increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis—a multicentre study in Japan. Nephrology Dialysis Transplantation 2007; 22(2): 560-567.
7. Xu T, Xie JY, Wang WM, Ren H, Chen N. Impact of rapamycin on peritoneal fibrosis and transport function. Blood Purification 2012; 34(1): 48-57.
8. Nishino T, Ashida R, Obata Y, Furusu A, Abe K et al. Involvement of Lymphocyte Infiltration in the Progression of Mouse Peritoneal Fibrosis Model. Renal Failure 2012; 34(6): 760-766.
9. Habib SM, Abrahams AC, Korte MR, Zietse R, de Vogel LL et al. CD4-positive T cells and M2 macrophages dominate the peritoneal infiltrate of patients with encapsulating peritoneal sclerosis. PLoS ONE 2015;10(4): e120174.
10. Cornish KS, Kuffova L, Forrester JV. Treatment of diffuse subretinal fibrosis uveitis with rituximab. British Journal of Ophthalmology 2015; 99(2): 153-154.
11. Giuggioli D, Lumetti F, Colaci M, Fallahi P, Antonelli A et al. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmunity Reviews 2015; 14(11): 1072-1078.
12. Nakamoto H. Encapsulating peritoneal sclerosis—a clinician’s approach to diagnosis and medical treatment. Peritoneal Dialysis International 2005; 25(4): 30-38.
13. Wong CF, Beshir S, Khalil A, Pai P, Ahmad R. Successful treatment of encapsulating peritoneal sclerosis with azathioprine and prednisolone. Peritoneal Dialysis International 2005; 25(3): 285-287.
14. Morath C, Arns W, Schwenger V, Mehrabi A, Fonouni H et al. Sirolimus in renal transplantation. Nephrology Dialysis Transplantation 2007; 22(8): 61-65.
15. Bircan L, Karakose S, Unverdi H, Bal AZ, Unverdi S et al. Abatacept as a therapeutic option in the treatment of encapsulated peritoneal sclerosis: an experimental rat model. International Urology and Nephrology 2017; 49(5): 909-916.
16. Davies A, Berge C, Boehnke A, Dadabhoy A, Lugtenburg P et al. Subcutaneous rituximab for the treatment of B-cell hematologic malignancies: A review of the scientific rationale and clinical development. Advances in Therapy 2017; 34(10): 2210-2231.
17. Ishii Y, Sawada T, Shimizu A, Tojimbara T, Nakajima I et al. An experimental sclerosing encapsulating peritonitis model in mice. Nephrology Dialysis Transplantation 2001; 16(6): 1262- 1266.
18. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M et al. Morphologic changes in the peritoneal membrane of patients with renal disease. Journal of the American Society of Nephrology 2002; 13(2): 470-479.
19. Jiang S, Tang Q, Rong R, Tang L, Xu M et al. Mycophenolate mofetil inhibits macrophage infiltration and kidney fibrosis in long-term ischemia-reperfusion injury. European Journal of Pharmacology 2012; 688(1-3): 56-61.
20. Goodlad C, Brown EA. Encapsulating peritoneal sclerosis: what have we learned? Seminars in Nephrology 2011; 31(2): 183-198.
21. Kawanishi H, Watanabe H, Moriishi M, Tsuchiya S. Successful surgical management of encapsulating peritoneal sclerosis. Peritoneal Dialysis International 2005; 25(4): 39-47.
22. Cornelis T, Oreopoulos DG. Update on potential medical treatments for encapsulating peritoneal sclerosis; human and experimental data. International Urology and Nephrology 2011; 43(1): 147-156.
23. Huddam B, Başaran M, Koçak G, Azak A, Yalçın F et al. The use of mycophenolate mofetil in experimental encapsulating peritoneal sclerosis. International Urology and Nephrology 2015; 47(8): 1423-1428.
24. Mondello S, Mazzon E, Di Paola R, Crisafulli C, Mondello P et al. Thalidomide suppresses peritoneal fibrosis in rat experimental model. Shock 2009; 32(3): 332-339.
25. Zhu F, Bai X, Chen X. B lymphocytes in renal interstitial fibrosis. Journal of Cell Communication and Signaling 2017; 11(3): 213- 218.
26. Thapa M, Chinnadurai R, Velazquez VM, Tedesco D, Elrod E et al. Liver fibrosis occurs through dysregulation of MyD88- dependent innate B-cell activity. Hepatology 2015; 61(6): 2067- 2079.
27. François A, Chatelus E, Wachsmann D, Sibilia J, Bahram S et al. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Research and Therapy 2013; 15(5): R168.
28. Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Seminars in Arthritis and Rheumatism 2015; 44(4): 428-436.
29. Yoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunology Letters 2018; 195: 76-82.
30. Snapper CM, Waegell W, Beernink H, Dasch JR. Transforming growth factor-beta 1 is required for secretion of IgG of all subclasses by LPS-activated murine B cells in vitro. Journal of Immunology 1993; 151(9): 4625-4636.
31. Bozkurt D, Sipahi S, Cetin P, Hur E, Ozdemir O et al. Does immunosuppressive treatment ameliorate morphology changes in encapsulating peritoneal sclerosis? Peritoneal Dialysis International 2009; 29(2): 206-210.
32. Ceri M, Unverdi S, Dogan M, Unverdi H, Karaca G et al. Effect of sirolimus on the regression of peritoneal sclerosis in an experimental rat model. International Urology and Nephrology 2012; 44(3): 977-982.
33. Waller JR, Brook NR, Bicknell GR, Murphy GJ, Nicholson ML. Mycophenolate mofetil inhibits intimal hyperplasia and attenuates the expression of genes favouring smooth muscle cell proliferation and migration. Transplantation Proceedings 2005; 37(1): 164-166.
34. Hur E, Bozkurt D, Timur O, Bicak S, Sarsik B et al. The effects of mycophenolate mofetil on encapsulated peritoneal sclerosis model in rats. Clinical Nephrology 2012; 77(1): 1-7.
35. Bozkurt D, Sarsik B, Hur E, Ertilav M, Karaca B et al. A novel angiogenesis inhibitor, sunitinib malate, in encapsulating peritoneal sclerosis. Journal of Nephrology 2011; 24(3):359-365.